Special Issue

Antibiotic Use and Antimicrobial Treatment of Sepsis, ICU Infections and Other Critical Infections

Message from the Guest Editor

Critical infections can lead to a high mortality. Critical infections are currently the most serious type of disease threatening the life of patients in ICUs. Infections in ICUs are the most common cause of preventable death. Some of the most-common serious infections in hospitals are pneumonia and sepsis. After critical infections, early antibiotic treatment is required. The use of ineffective antibiotics and low-dose antibiotics has led to the emergence of more and more resistant strains, and thus the use of antibiotics in critical infections needs to be optimized. The ability of early empirical antibiotic therapy to effectively fight the pathogens of severe infections has a great impact on prognosis. This Special Issue focuses on manuscripts related to the antibiotic use and antimicrobial treatment of sepsis and critical infections. This Special Issue welcomes contributions that explore antibiotics and antibacterial therapy in sepsis, ICU infections and other critical infections, from basic science to clinical medicine, including the optimization of antibiotic use, pharmacokinetics, and research into related drug-resistant pathogens.

Guest Editor

Dr. Yutaka Kondo
Department of Emergency and Critical Care Medicine, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan

Deadline for manuscript submissions

closed (31 August 2023)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/120549

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI